Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects

Core Insights - Milestone Pharmaceuticals (NASDAQ:MIST) is currently viewed as a promising investment opportunity, with analysts at Jefferies raising the price target from $1 to $2, maintaining a Hold rating [1][2]. Company Overview - Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for self-administration by patients with episodic heart conditions [3]. Product Development and Sales Prospects - The price target increase is attributed to the company's confidence in its upcoming PDUFA, with a product launch scheduled for early next year [2]. - The company anticipates that the first quarter of next year will mark the beginning of significant sales, supported by the deployment of 60 representatives targeting up to 15,000 high-volume prescribers [2]. - Milestone is developing Etripamil, a nasal-administered, short-acting calcium channel blocker aimed at treating paroxysmal supraventricular tachycardia (PSVT) [2].